Please assess the completion status of the following clinical trial:

Trial Title: Masitinib in Patients With Gastro-Intestinal Stromal Tumour Resistant to Imatinib

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Histological proven, metastatic, or locally advanced and non-operable GIST~2. Measurable tumor lesions with longest diameter ≥ 20 mm using conventional techniques or ≥ 10 mm with spiral CT scan according RECIST criteria~3. C-kit (CD117) positive tumors detected immuno-histochemically and documented mutation of c-kit at any time if available~4. Patients resistant to imatinib at dose of 400 mg/day~Exclusion Criteria:~1. Patient treated for a cancer other than GIST cancer within 5 years before enrolment, with the exception of basal cell carcinoma or cervical cancer in situ~2. Patient with active central nervous system (CNS) metastasis or with history of CNS metastasis

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- masitinib (Type: EXPERIMENTAL): masitinib 12 mg/kg/day
- sunitinib (Type: ACTIVE_COMPARATOR): sunitinib 50 mg/day

Based on this trial design, predict the completion outcome and termination type (if applicable).